Dr. Wei Hongxiang is an emerging clinical researcher in orthopedics whose scholarly contributions reflect a strong commitment to advancing bone tumor therapy, nanomedicine, and neuroimmune regulatory mechanisms. With a research output comprising 17 documents, an h-index of 8, and more than 462 citations, his work demonstrates both productivity and meaningful scientific impact across interdisciplinary domains. Dr. Wei has made notable advancements in osteosarcoma-targeted therapeutics, particularly through the development of mesenchymal stem cell–derived exosome nanodrug delivery systems for doxorubicin, offering enhanced precision and reduced systemic toxicity. His studies on molecular diagnostic technologies, ultrasensitive detection platforms, and tumor microenvironment biomarkers have further contributed to early detection and improved clinical management of bone malignancies. In collaboration with leading experts, he has published high-quality research in reputable journals, including Q1-ranked international publications in nanomedicine, analytical chemistry, and clinical pathology, strengthening the translational value of his findings. His work also spans important investigations into tumor progression signaling pathways, therapeutic resistance mechanisms, and novel intervention targets such as BUB1, NLRP3, EGFR, and gasdermin D. Beyond journal articles, Dr. Wei has contributed to innovative medical device and pharmaceutical patents, demonstrating strong applied research potential within orthopedic oncology. With academic training across clinical medicine, orthopedic surgery, and doctoral-level specialization, supported by national scholarships and professional medical licensing, he brings a well-rounded clinical-scientific perspective to orthopedic tumor research. Dr. Wei’s ongoing focus on bone tumor biology, neuroimmune interactions, and cutting-edge diagnostic platforms positions him as a rising researcher dedicated to improving cancer treatment outcomes and expanding the frontiers of orthopedic oncology.